MX9702431A - Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same. - Google Patents
Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same.Info
- Publication number
- MX9702431A MX9702431A MX9702431A MX9702431A MX9702431A MX 9702431 A MX9702431 A MX 9702431A MX 9702431 A MX9702431 A MX 9702431A MX 9702431 A MX9702431 A MX 9702431A MX 9702431 A MX9702431 A MX 9702431A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- enteric bacteria
- bacteria
- enteric
- vaccines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/045—Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced enteric bacteria. Also methods for using the antigenically enhanced bacteria are also disclosed, as well as vaccines containing the enteric bacteria. Specifically, a whole enteric bacteria or components thereof are provided by Helicobacter species. Also there are other enteric bacteria which are useful for the disclosed invention. One type, Campylobacter jejuni is graphically depicted wherein the results of high-performance liquid chromatography of monosaccharides from surface extract hydrolysates of C. jejuni are shown.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31840994A | 1994-10-05 | 1994-10-05 | |
US08/538,545 US5679564A (en) | 1994-10-05 | 1995-10-03 | Methods for producing enhanced antigenic campylobacter bacteria and vaccines |
US08/538,543 US5681736A (en) | 1994-10-05 | 1995-10-03 | Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same |
PCT/US1995/013196 WO1996011258A1 (en) | 1994-10-05 | 1995-10-04 | Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9702431A true MX9702431A (en) | 1998-05-31 |
Family
ID=27405987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9702431A MX9702431A (en) | 1994-10-05 | 1995-10-04 | Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0804542A4 (en) |
JP (1) | JP3394047B2 (en) |
CN (1) | CN1168693A (en) |
AU (1) | AU704283B2 (en) |
BR (1) | BR9509276A (en) |
CA (1) | CA2202027A1 (en) |
CZ (1) | CZ104397A3 (en) |
FI (1) | FI971403A (en) |
HU (1) | HUT77876A (en) |
IL (1) | IL115521A0 (en) |
MX (1) | MX9702431A (en) |
NO (1) | NO971519L (en) |
NZ (1) | NZ295907A (en) |
PL (1) | PL182700B1 (en) |
SG (2) | SG73510A1 (en) |
WO (1) | WO1996011258A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0792347B1 (en) * | 1994-10-05 | 2005-11-23 | Antex Biologics, Inc. | Methods for producing enhanced antigenic helicobacter sp. and vaccines comprising same |
CA2525540A1 (en) * | 2003-05-30 | 2004-12-09 | Intercell Ag | Enterococcus antigens |
EP1996228A4 (en) * | 2006-03-17 | 2009-08-26 | Cerebus Biolog Inc | Campylobacter vaccines and methods of use |
JP5398527B2 (en) * | 2007-05-28 | 2014-01-29 | 北里第一三共ワクチン株式会社 | Parapertussis whole cell vaccine composition |
CN107513553B (en) * | 2017-09-18 | 2021-05-18 | 江南大学 | Method for screening lactobacillus with antagonistic campylobacter jejuni infection function |
CN109633151B (en) * | 2018-12-26 | 2022-03-11 | 西北农林科技大学 | Salmonella enteritidis detection method, test strip and application |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU657168B2 (en) * | 1991-09-18 | 1995-03-02 | Amgen, Inc. | Hepatitis B vaccine with bile salt adjuvant |
-
1995
- 1995-10-04 BR BR9509276A patent/BR9509276A/en not_active Application Discontinuation
- 1995-10-04 SG SG1998000819A patent/SG73510A1/en unknown
- 1995-10-04 WO PCT/US1995/013196 patent/WO1996011258A1/en not_active Application Discontinuation
- 1995-10-04 CA CA002202027A patent/CA2202027A1/en not_active Abandoned
- 1995-10-04 CZ CZ971043A patent/CZ104397A3/en unknown
- 1995-10-04 SG SG1998000815A patent/SG73509A1/en unknown
- 1995-10-04 AU AU39561/95A patent/AU704283B2/en not_active Ceased
- 1995-10-04 PL PL95319580A patent/PL182700B1/en not_active IP Right Cessation
- 1995-10-04 JP JP51271696A patent/JP3394047B2/en not_active Expired - Fee Related
- 1995-10-04 EP EP95937449A patent/EP0804542A4/en not_active Withdrawn
- 1995-10-04 MX MX9702431A patent/MX9702431A/en not_active IP Right Cessation
- 1995-10-04 CN CN95196589A patent/CN1168693A/en active Pending
- 1995-10-04 NZ NZ295907A patent/NZ295907A/en unknown
- 1995-10-04 HU HU9702303A patent/HUT77876A/en unknown
- 1995-10-05 IL IL11552195A patent/IL115521A0/en unknown
-
1997
- 1997-04-03 NO NO971519A patent/NO971519L/en not_active Application Discontinuation
- 1997-04-04 FI FI971403A patent/FI971403A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL319580A1 (en) | 1997-08-18 |
NZ295907A (en) | 1999-04-29 |
WO1996011258A1 (en) | 1996-04-18 |
CN1168693A (en) | 1997-12-24 |
IL115521A0 (en) | 1996-06-18 |
CA2202027A1 (en) | 1996-04-18 |
EP0804542A1 (en) | 1997-11-05 |
SG73510A1 (en) | 2000-06-20 |
JP3394047B2 (en) | 2003-04-07 |
NO971519L (en) | 1997-05-27 |
CZ104397A3 (en) | 1998-06-17 |
FI971403A (en) | 1997-06-04 |
HUT77876A (en) | 1998-09-28 |
FI971403A0 (en) | 1997-04-04 |
AU3956195A (en) | 1996-05-02 |
EP0804542A4 (en) | 1998-10-28 |
AU704283B2 (en) | 1999-04-15 |
BR9509276A (en) | 1997-11-18 |
PL182700B1 (en) | 2002-02-28 |
JPH10507347A (en) | 1998-07-21 |
SG73509A1 (en) | 2000-06-20 |
NO971519D0 (en) | 1997-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES500567A0 (en) | PROCEDURE FOR PREPARING VACCINATION COMPLEXES BY REACTION OF RIBONOSAL RNA AND SPECIFIC ANTIGENS. | |
MY133780A (en) | Vaccine composition | |
MY113428A (en) | Hepatitis b vaccine | |
HUP0302965A2 (en) | Vaccine | |
WO1998056901A3 (en) | Live attenuated vaccines | |
GB8412207D0 (en) | Antigenic preparations | |
NZ223009A (en) | Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens | |
HUP9903770A2 (en) | Method and composition for reconforming multi-epitopic antigens to initiate an immune response | |
EP0722338A4 (en) | Protein- or peptide-cochleate vaccines and methods of immunizing using the same | |
MY128999A (en) | Purification of hbv antigens for use in vaccines | |
NZ314585A (en) | Method of treating H. Pylori associated gastroduodenal disease | |
MX9702432A (en) | Methods for producing enhanced antigenic helicobacter sp. and vaccines comprising same. | |
MX9702431A (en) | Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same. | |
IE42622L (en) | Protective antigen from pertussis. | |
DE69527986T2 (en) | ANTIGENE MEDICINE FOR TREATMENT OR PREVENTION | |
ZA905927B (en) | Biological preparation and its use | |
CY1934A (en) | Process | |
EP0090660A3 (en) | Neisseria gonorrhoeae vaccine | |
WO2004033483A3 (en) | Liposomal system and method of using same | |
UA42741C2 (en) | Peptide of mastitis vaccine (variants), the peptide of complex antigenic idea (variants), pharmaceutical composition (variants) | |
ATE353226T1 (en) | ADJUVANT COMPOSITION CONTAINING FHA OR AN FHA FRAGMENT IN FREE FORM | |
AU2579600A (en) | Product and method for obtaining specific immunisation with one or more antigens | |
EP0563288A4 (en) | Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines | |
EP0520263A3 (en) | Process for the preparation of 2-methylenpropane-1,3-diol dicarboxylates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |